TO FINANCIAL STATEMENTS
to Financial Statements
this report, “Stereotaxis”, the “Company”, “Registrant”, “we”, “us”,
and “our” refer to Stereotaxis, Inc. and its wholly owned subsidiaries. Epoch®, Niobe®,
Odyssey®, Odyssey Cinema™, Vdrive®, Vdrive Duo™, V-CAS™,
V-Loop™, V-Sono™, V-CAS Deflect™, QuikCAS™ and Cardiodrive®
are trademarks of Stereotaxis, Inc. All other trademarks that appear in this report are the property of their respective
Description of Business
designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in
a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment
of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional,
procedures. The Epoch Solution is comprised of the Niobe ES Robotic Magnetic Navigation System (“Niobe
ES system”), Odyssey Information Management Solution (“Odyssey Solution”), and the Vdrive
Robotic Navigation System (“Vdrive system”), and related devices.
Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image-guided
delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally
applied magnetic fields that govern the motion of the working tip of the catheter resulting in improved navigation, efficient
procedures and reduced x-ray exposure. As of December 31, 2018, the Company had an installed base of 126 Niobe ES systems.
addition to the robotic magnetic system and its components, Stereotaxis also has developed the Odyssey Solution, which
consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features
a remote viewing and recording capability called Odyssey Cinema, which is an innovative solution delivering synchronized
content for optimized workflow, advanced care and improved productivity. This tool includes an archiving capability that allows
clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout
the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration,
remote consultation and training.
Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional
procedures. The Vdrive system complements the robotic magnetic system control of therapeutic catheters for fully remote
procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo
system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable
components which can be manipulated by these systems.
promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The
full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The
upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable
costs for each procedure and equipment service costs beyond warranty period. In hospitals where the full Epoch Solution
has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion.
core components of Stereotaxis systems, such as Niobe system, Odyssey Solution, Cardiodrive and various disposable
interventional devices have received regulatory clearance in the U.S., Europe, Canada, China, Japan and various other countries.
We have received the regulatory clearance, licensing and/or CE Mark approvals that allow us to market the Vdrive and
Vdrive Duo systems with the V-CAS, V-Loop and V-Sono devices in the U.S., Canada and Europe. The
V-CAS Deflect catheter advancement system has been CE Marked for sale in Europe.
Summary of Significant Accounting Policies
Company believes the cash on hand at December 31, 2018 will be sufficient to meet its obligations as they become due in the
ordinary course of business for at least 12 months following the date these financial statements are issued. The Company has sustained
operating losses throughout its corporate history and expects that its 2019 expenses will exceed its 2019 gross margin. The Company
expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing
operations or expense reductions are in place. The Company’s liquidity needs will be largely determined by the success of
clinical adoption within the installed base of robotic magnetic systems and placement of new robotic magnetic systems as
well as by new placements of capital systems. The Company also may consider raising cash through capital transactions, which could
include either debt or equity financing.
and Cash Equivalents
Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents.
The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. No
cash was restricted at December 31, 2018 or 2017.